The activation of macrophages has been suggested to boost MASLD progression by either exaggerating liver steatosis via inhibition of the PPARα signaling pathway in hepatocytes or by promoting the activation of HSCs through enhancement of Tnf and Il1b [39,40]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.